433695-36-4
433695-36-4 结构式
基本信息
5-NITRO-2,N,N-TRIMETHYLBENZENESULFONAMIDE
N,N,2-TRIMETHYL-5-NITRO-BENZENESULFONAMIDE
Benzenesulfonamide, N,N,2-trimethyl-5-nitro-
3-(N,N-Dimethylsulfonamido)-4-methylnitrobenzene,5-Nitro-2-N,N-trimethylbenzenesulfonamide
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-109586 | N,N,2-三甲基-5-硝基苯磺酰胺 BRL-50481 | 433695-36-4 | 5mg | 500元 |
| 2024/01/25 | HY-109586 | N,N,2-三甲基-5-硝基苯磺酰胺 BRL-50481 | 433695-36-4 | 10mM * 1mLin DMSO | 550元 |
| 2024/01/25 | HY-109586 | N,N,2-三甲基-5-硝基苯磺酰胺 BRL-50481 | 433695-36-4 | 10mg | 650元 |
常见问题列表
IC50: 0.15 μM (PDE7A), 12 μM (PDE7B), 62 μM (PDE4), 490 μM (PDE3)
BRL-50481 increases the cAMP content (19.1±6.2% of IBMX response at 300 μM) but is considerably less potent. BRL-50481 (30 μM) fails to suppress proliferation by itself but significantly potentiates the effect of rolipram. BRL-50481 (30 μM) has no effect on IL-15-induced proliferation but augments the inhibitory effect of rolipram. Pretreatment (30 min) of human monocytes with BRL-50481 has, by itself, a negligible (~2 to 10%) inhibitory effect on TNFα output at all concentrations tested. BRL-50481 also potentiates the inhibitory effect of PGE 2 on LPS-induced TNFα release. BRL-50481 has no significant effect by itself on κB-dependent transcription (5.6±1.9% inhibition at 30 μM) and fails to enhance the effect of rolipram (maximum inhibition, 52.9±2.7%; pIC 30 value of 5.33±0.12). BRL-50481 suppresses, in a concentration-dependent manner, LPS-induced TNFα release in monocytes in which PDE7A1 is induced (21.7±1.6% inhibition at 30 μM at the 12-h time point).